Of note, new imaging modalities, such choline positron-emission tomography (PET) or prostate-specific membrane antigen tomography (PET-PSMA), have shown the ability to identify metastatic disease in the majority of non-metastatic patients by conventional imaging [37]. Here, FOLH1 is linked to metastatic neoplasm.